Reagan Seeks 5.4% Boost at NIH

WASHINGTON—The proposed 5.4 percent increase next year for NIH is expected to be taken more seriously by Congress than previous budgets that President Reagan has submitted for health research. The 1989 request would lift the current NIH budget of $6.667 billion to $7.123 billion, a figure that includes $588 million for AIDS research. Last year NIH received $448 million for AIDS, a little less than one-half of the total federal spending on the disease. “This is the most realisti

Written byAj Hostetler
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

WASHINGTON—The proposed 5.4 percent increase next year for NIH is expected to be taken more seriously by Congress than previous budgets that President Reagan has submitted for health research.

The 1989 request would lift the current NIH budget of $6.667 billion to $7.123 billion, a figure that includes $588 million for AIDS research. Last year NIH received $448 million for AIDS, a little less than one-half of the total federal spending on the disease.

“This is the most realistic budget we’ve sent up in a long time,” observed one NIH legislative staff member. The aide speculated that the modest size of the proposal could make it difficult for Congress to follow past practice and write its own budget that provides for greater increases.

Last year Congress ignored Reagan’s request to trim NIH’s budget and approved double-digit increases for several institutes and for the fight against AIDS.

"It should be acknowledged ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies